Maitake Products, Inc. (MPI), Ridgefield Park, NJ announces today that it has started selling a new Maitake extract, “TD-Fraction Powder” which has been standardized to contain a minimum of 10% D-fraction in the product. D-fraction is well known in the market place as an active compound (protein-bound beta-glucan or proteoglucan) to enhance cellular immune activities and induce apoptosis (programmed cell death) of certain cancer cells. It is designed to be most potent when taken orally, unlike pure beta-glucans, which are only effective by IV injection.
MPI’s flagship product, MAITAKE D-FRACTION® is based on a more purified standardized extract (Pre D-Fraction powder), and guarantees a 30% content of the active D-fraction. This finished product has been approved by the FDA for conducting a phase 2 clinical study as an IND (Investigational New Drug) for advanced breast and prostate cancer patients (#54, 589). The 30% standardized extract (Pre D-Fraction) has been popular, but available only in a very limited way due to the high extraction cost involved in its production. Only a few leading supplement manufacturers, such as Enzymatic Therapy, Pure Encapsulations and Nuways, have employed the extract as one of the key active ingredients for their immune enhancing products.
Hideo Anzai, Vice President of Scientific Affairs for MPI, claims that the new maitake standardized extract, TD-Fraction powder, is ideal for immune enhancing products in either tablet or capsule form and will become very popular due to its reasonable price and ease of manufacturing. It is less than 1/5 of the Pre D-Fraction price although the D-fraction content is 1/3 of that of the Pre D-Fraction. We have already received a significant number of orders from several manufacturers for the TD-Fraction. This is due to the recognized credentials and market availability of “Maitake D-Fraction®” which is well known in the industry. For information about the TD-Fraction powder, please call 1-800-747-7418 or email [email protected].